Hannah C Timmins1, Tiffany Li1, David Goldstein2,3, Terry Trinh2, David Mizrahi2, Michelle Harrison4,5, Lisa G Horvath4,6,7, Michael Friedlander2,5, Matthew C Kiernan1,6,7, Susanna B Park8. 1. Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2050, Australia. 2. Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. 3. Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia. 4. Chris O'Brien Lifehouse, Sydney, Australia. 5. Department of Medical Oncology, Liverpool Hospital, Liverpool, Australia. 6. Sydney Medical School, University of Sydney, Camperdown, Australia. 7. Royal Prince Alfred Hospital, Camperdown, Australia. 8. Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2050, Australia. susanna.park@sydney.edu.au.
Abstract
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of neurotoxic cancer treatment, often impacting treatment tolerability and patient functioning. Factors predicting an individual's vulnerability for developing CIPN remain ill-defined. However, patient characteristics may contribute to CIPN risk, with obesity being a prevalent patient comorbidity. This study was aimed at evaluate if being overweight (BMI ≥ 25 kg/m2) was associated with worse symptomatic, clinical, and functional CIPN following neurotoxic cancer treatment. METHODS: Three hundred seventy-nine cancer survivors were assessed 5 (IQR 3-5) months post oxaliplatin or paclitaxel treatment via comprehensive patient-reported, clinical, and functional CIPN measures. Patients classified as overweight (BMI ≥ 25 kg/m2) were compared to those within the normal BMI range (< 25 kg/m2). Multilinear regression was conducted to evaluate the association between patient clinical factors and CIPN severity. RESULTS: Most patients reported CIPN symptoms (78%), with deficits evident on clinical examination. Overweight patients (n = 242, 63.8%) had significantly worse CIPN across symptomatic, objective clinical, and functional outcomes compared to those with a normal BMI (p < .05). In multivariate linear regression, older age (B = .088, 95%CI = .053-.122, p < .001), larger waist circumference (B = .030, 95%CI = .001-.059, p < .05), and larger BSA (B = 2.41, 95%CI = .34-04.48, p < .05) were associated with CIPN. Diabetes and BMI were significant on univariate analysis but not in the final models. CONCLUSIONS: Overweight patients represent a large proportion of cancer survivors who may be particularly impacted by CIPN, requiring closer monitoring and referral to supportive services. Accessible data such as a patient's general and abdominal obesity status may aid in formulating personalized treatment. IMPLICATIONS FOR CANCER SURVIVORS: Identifying routinely measured patient characteristics which may contribute to an individual's CIPN risk profile could assist with informing treatment decisions.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a major side effect of neurotoxic cancer treatment, often impacting treatment tolerability and patient functioning. Factors predicting an individual's vulnerability for developing CIPN remain ill-defined. However, patient characteristics may contribute to CIPN risk, with obesity being a prevalent patient comorbidity. This study was aimed at evaluate if being overweight (BMI ≥ 25 kg/m2) was associated with worse symptomatic, clinical, and functional CIPN following neurotoxic cancer treatment. METHODS: Three hundred seventy-nine cancer survivors were assessed 5 (IQR 3-5) months post oxaliplatin or paclitaxel treatment via comprehensive patient-reported, clinical, and functional CIPN measures. Patients classified as overweight (BMI ≥ 25 kg/m2) were compared to those within the normal BMI range (< 25 kg/m2). Multilinear regression was conducted to evaluate the association between patient clinical factors and CIPN severity. RESULTS: Most patients reported CIPN symptoms (78%), with deficits evident on clinical examination. Overweight patients (n = 242, 63.8%) had significantly worse CIPN across symptomatic, objective clinical, and functional outcomes compared to those with a normal BMI (p < .05). In multivariate linear regression, older age (B = .088, 95%CI = .053-.122, p < .001), larger waist circumference (B = .030, 95%CI = .001-.059, p < .05), and larger BSA (B = 2.41, 95%CI = .34-04.48, p < .05) were associated with CIPN. Diabetes and BMI were significant on univariate analysis but not in the final models. CONCLUSIONS: Overweight patients represent a large proportion of cancer survivors who may be particularly impacted by CIPN, requiring closer monitoring and referral to supportive services. Accessible data such as a patient's general and abdominal obesity status may aid in formulating personalized treatment. IMPLICATIONS FOR CANCER SURVIVORS: Identifying routinely measured patient characteristics which may contribute to an individual's CIPN risk profile could assist with informing treatment decisions.
Authors: Eric P Davidson; Lawrence J Coppey; Nigel A Calcutt; Christine L Oltman; Mark A Yorek Journal: Diabetes Metab Res Rev Date: 2010-05 Impact factor: 4.876
Authors: Dawn L Hershman; Cathee Till; Jason D Wright; Danielle Awad; Scott D Ramsey; William E Barlow; Lori M Minasian; Joseph Unger Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Dawn L Hershman; Christina Lacchetti; Robert H Dworkin; Ellen M Lavoie Smith; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Patrick Gavin; Antoinette Lavino; Maryam B Lustberg; Judith Paice; Bryan Schneider; Mary Lou Smith; Tom Smith; Shelby Terstriep; Nina Wagner-Johnston; Kate Bak; Charles L Loprinzi Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Jetter Robertson; Jeffrey Raizer; James S Hodges; William Gradishar; Jeffrey A Allen Journal: J Peripher Nerv Syst Date: 2018-05-11 Impact factor: 3.494
Authors: Brian C Callaghan; Rong Xia; Evan Reynolds; Mousumi Banerjee; Amy E Rothberg; Charles F Burant; Emily Villegas-Umana; Rodica Pop-Busui; Eva L Feldman Journal: JAMA Neurol Date: 2016-12-01 Impact factor: 18.302
Authors: Myra Barginear; Amylou C Dueck; Jacob B Allred; Craig Bunnell; Harvey J Cohen; Rachel A Freedman; Arti Hurria; Gretchen Kimmick; Jennifer G Le-Rademacher; Stuart Lichtman; Hyman B Muss; Lawrence N Shulman; M Sitiki Copur; David Biggs; Bhuvaneswari Ramaswamy; Jacqueline M Lafky; Aminah Jatoi Journal: Oncologist Date: 2018-11-08
Authors: Brian C Callaghan; Evan Reynolds; Mousumi Banerjee; Ericka Chant; Emily Villegas-Umana; Eva L Feldman Journal: Mayo Clin Proc Date: 2020-07 Impact factor: 7.616
Authors: Willemieke P M Dijksterhuis; Maarten J Pruijt; Stephanie O van der Woude; Remy Klaassen; Sophie A Kurk; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: J Cachexia Sarcopenia Muscle Date: 2019-01-21 Impact factor: 12.910
Authors: Justin C Brown; Jeffrey A Meyerhardt; Elizabeth M Cespedes Feliciano; En Cheng; Bette J Caan Journal: Clin Nutr Date: 2022-05-27 Impact factor: 7.643
Authors: Lishi Lin; Marcel Soesan; Dorieke E M van Balen; Jos H Beijnen; Alwin D R Huitema Journal: Breast Cancer Res Treat Date: 2022-08-16 Impact factor: 4.624